Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
about
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.[Use of intracutaneous or subcutaneous botulinum toxin for postherpetic neuralgia].Effect of 3 Commercially Available Botulinum Toxin Neuromodulators on Facial Synkinesis: A Randomized Clinical Trial.Intragastric Botolinum Toxin-A Injection as a Treatment for Obesity in Comparison to Gastric Balloon.Botulinum neurotoxin formulations: overcoming the confusion.Unilateral Botulinum Neurotoxin-A Injection into the Striatum of C57BL/6 Mice Leads to a Different Motor Behavior Compared with RatsTreatment of non-odontogenic orofacial pain using botulinum toxin-A: a retrospective case series study
P2860
Q39207459-E9775C4F-2477-4B97-B63A-D488E8B93EB4Q40421111-801437CA-4096-4A76-83BD-D2790C6BFBD4Q47253498-DC911DD1-6AED-461F-BA3E-CC1D544E534FQ48156555-E73BED95-D9D3-402B-BC54-D16F79C0BCA8Q55260245-EDCFD8D3-8BF4-4BD6-ACDA-F47F80D2F609Q57515344-54B2A092-7623-47A3-8EAC-3CF047D95DADQ58798782-013522D1-5A28-41BD-9F80-0EEA6CB7EBEB
P2860
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
@ast
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
@en
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
@nl
type
label
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
@ast
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
@en
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
@nl
prefLabel
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
@ast
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
@en
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
@nl
P2860
P356
P1433
P1476
Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice
@en
P2093
Francesco Scaglione
P2860
P356
10.3390/TOXINS8030065
P407
P577
2016-03-01T00:00:00Z
2016-03-04T00:00:00Z